AstraZeneca says late-stage trials of its Covid-19 vaccine were “highly effective” in preventing disease.
A vaccine developed by AstraZeneca and the University of Oxford prevented 70 per cent of people from developing the coronavirus in late-stage trials, the team reported Monday.
Key researcher Dr Andrew Pollard said scientists were pleased with the results. He said researchers found that if people were given a half dose followed by a full dose, rather than two full doses, protection rose to about 90 per cent.
“These findings show that we have an effective vaccine that will save many lives,” he said.
Two other drugmakers, Pfizer and Moderna, last week reported preliminary results from late-stage trials showing that their Covid-19 vaccines were almost 95 per cent effective.
For in-depth, objective and more importantly balanced journalism, Click here to subscribe to Outlook Magazine
This article is auto-generated by Algorithm Source: www.outlookindia.com
